A woman holds an Eli Lilly slimming syringe bearing the name Mounjaro and the active ingredient tirzepatide. Photo: Christoph Reichwein/dpa (Photo by Christoph Reichwein/photo alliance via Getty Images)
Apothecary Pharma is recalling 23 vials of injectable medications distributed nationwide because their sterility cannot be guaranteed, according to the Food and Drug Administration.
Dig Deeper:
The voluntary recall includes 22 vials of compound tirzepatide, a GLP-1 drug containing the same active ingredient as Mounjaro and Eli Lilly’s Zepbound, as well as one vial of NAD+ injection. The FDA classified the recall as Class II on October 8, meaning serious health problems are unlikely.
RELATED: Cheddar cheese recalled in several states due to dangerous E. coli
The recall comes after the FDA sent Apothecary Pharma, a North Carolina company, a warning letter in December 2025 citing serious deficiencies in its sterile drug manufacturing practices. The agency said these issues posed risks to patients, but did not link these findings to the current recall.
What you need to know about GLP-1 and cannabis use
Dr. Jordan Tishler, cannabis physician and president of the Association of Cannabinoid Specialists, talks with FOX Local’s Heather Miller about potential interactions between cannabis and popular weight-loss drugs.
The affected tirzepatide is a prescription injection of 18 mg/mL packaged in a 4 mL multidose vial. Its NDC number is 85091-001-18. Recalled lots include AP-202622 to AP-202625 and AP-202627 to AP-202644, with best-before dates ranging from October 7 to November 26, 2026.
The recalled NAD+ injection is a 200 mg/mL prescription product packaged in a 6 mL multidose vial. Its NDC number is 85091-011-06. The affected batch is AP-202647, with a best-before date of October 13, 2026.
Apothecary Pharma began the recall on September 24 and notified recipients by letter. The recall is in progress.
What you can do:
Consumers should check their bottles or pharmaceutical records, stop using the affected products and contact their pharmacist or prescriber for advice. Anyone who experiences fever, redness, swelling, or worsening pain after receiving an affected injection should seek medical attention.
The FDA notice did not report any illnesses or injuries associated with the recalled products.
The source : FOX Business contributed to this report. The information in this story comes from a recall notice issued by the Food and Drug Administration. This story was reported from Los Angeles.
Gn bussni
